The FDA approval was based on positive data from the Augment-101 clinical trial, where Revuforj delivered robust and durable rates of remission in r/r acute leukemia patients with a kmt2a ...
Syndax Pharmaceuticals won the first FDA approval last week in a new class of medicines called menin inhibitors. The treatment, Rejuforj, will be available as soon as this month for patients with an ...
Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...
The FDA-cleared Spectral CT 7500 RT, a detector-based computed tomography radiotherapy solution aimed to enhance radiation ...
BTIG raised the firm’s price target on Syndax (SNDX) to $43 from $35 and keeps a Buy rating on the shares. The firm cites the company having ...
The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals’ Revuforj (revumenib). Revuforj is the first ...
The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...
The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory ...
The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...
Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...
H.C. Wainwright raised the firm’s price target on Syndax (SNDX) to $51 from $49 and keeps a Buy rating on the shares after Revuforj received FDA approval for acute leukemia with KMT2A translocation.
Revuforj was approved to treat adults and children with relapsed or refractory leukemias that have a genetic “rearrangement” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback